|
HU1100562A2
|
|
Erlotinib salts
|
|
HU1100561A2
|
|
Cocrystals of rivaroxaban for producing pharmaceutical compositions
|
|
HU1100207A2
|
|
Modified release pharmaceutical formulation
|
|
HU1000637D0
|
|
A process for the preparation of high purity pharmaceutical intermediates
|
|
HU1000638D0
|
|
Process for preparation of rosuvastatin salts
|
|
HU1000624D0
|
|
Novel salts suitable for the preparation of pharmaceutical compositions
|
|
HU1000616D0
|
|
Process for preparation of rosuvastatin salt
|
|
HU1000565D0
|
|
Process for the preparation of pharmaceutically active compound and intermediers
|
|
HU1000547D0
|
|
Process to produce suitable auxiliary material for use in pharmaceutical industry
|
|
HU1000444D0
|
|
Process for the preparation of a pharmaceutical active ingredient
|
|
HU1000429D0
|
|
Febuxostat Diethylammonium salt
|
|
HU1000430D0
|
|
New polymorphous and solvate forms of a pharmaceutical active ingredient
|
|
HU1000431D0
|
|
Acid addition salts of a pharmaceutical active ingredient
|
|
HU1000362D0
|
|
Antiseptic and disinfecting compositions having reduced iodine content
|
|
HU0900455D0
|
|
Paliperidone salts for preparing pharmaceutical compositions
|
|
HU0900353A2
|
|
Glycerol-free osmotic type laxative suppository
|
|
HU0900352D0
|
|
Process for producing pharmaceutical active ingredient of certain crystalline size and of high purity
|
|
HU0900209D0
|
|
Process for the preparation of cyclohexanol derivatives
|
|
HU0800591D0
|
|
Stable combination drug
|
|
HU0800399D0
|
|
Process for the preparation of 1-(3,4-dimethoxy-phenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine with high purity
|
